Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Towards personalized computer simulation of breast cancer treatment: a multi-scale pharmacokinetic and pharmacodynamic model informed by multi-type patient data.

Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børressen-Dale AL, Kristensen VN, Engebråten O, Köhn-Luque A, Frigessi A.

Cancer Res. 2019 May 22. pii: canres.1804.2018. doi: 10.1158/0008-5472.CAN-18-1804. [Epub ahead of print]

PMID:
31118201
2.

Breast cancer quantitative proteome and proteogenomic landscape.

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF, Schlichting E, Naume B; Consortia Oslo Breast Cancer Research Consortium (OSBREAC), Luders T, Borgen E, Kristensen VN, Russnes HG, Lingjærde OC, Mills GB, Sahlberg KK, Børresen-Dale AL, Lehtiö J.

Nat Commun. 2019 Apr 8;10(1):1600. doi: 10.1038/s41467-019-09018-y.

3.

Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations.

Höglander EK, Nord S, Wedge DC, Lingjærde OC, Silwal-Pandit L, Gythfeldt HV, Vollan HKM, Fleischer T, Krohn M, Schlitchting E, Borgen E, Garred Ø, Holmen MM, Wist E, Naume B, Van Loo P, Børresen-Dale AL, Engebraaten O, Kristensen V.

Genome Med. 2018 Nov 29;10(1):92. doi: 10.1186/s13073-018-0601-y.

4.

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients.

Borgen E, Rypdal MC, Sosa MS, Renolen A, Schlichting E, Lønning PE, Synnestvedt M, Aguirre-Ghiso JA, Naume B.

Breast Cancer Res. 2018 Oct 16;20(1):120. doi: 10.1186/s13058-018-1049-0.

5.

Circulating Tumor Cells are an Independent Predictor of Shorter Survival in Patients Undergoing Resection for Pancreatic and Periampullary Adenocarcinoma.

Hugenschmidt H, Labori KJ, Brunborg C, Verbeke CS, Seeberg LT, Schirmer CB, Renolen A, Borgen EF, Naume B, Wiedswang G.

Ann Surg. 2018 Sep 13. doi: 10.1097/SLA.0000000000003035. [Epub ahead of print]

PMID:
30216219
6.

Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study.

Tinholt M, Garred Ø, Borgen E, Beraki E, Schlichting E, Kristensen V, Sahlberg KK, Iversen N.

J Thromb Haemost. 2018 Jul;16(7):1347-1356. doi: 10.1111/jth.14151. Epub 2018 Jun 12.

PMID:
29766637
7.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
8.

Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.

Helland T, Henne N, Bifulco E, Naume B, Borgen E, Kristensen VN, Kvaløy JT, Lash TL, Alnæs GIG, van Schaik RH, Janssen EAM, Hustad S, Lien EA, Mellgren G, Søiland H.

Breast Cancer Res. 2017 Nov 28;19(1):125. doi: 10.1186/s13058-017-0916-4.

9.

Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.

Ohnstad HO, Borgen E, Falk RS, Lien TG, Aaserud M, Sveli MAT, Kyte JA, Kristensen VN, Geitvik GA, Schlichting E, Wist EA, Sørlie T, Russnes HG, Naume B.

Breast Cancer Res. 2017 Nov 14;19(1):120. doi: 10.1186/s13058-017-0911-9.

10.

DNA methylation at enhancers identifies distinct breast cancer lineages.

Fleischer T, Tekpli X, Mathelier A, Wang S, Nebdal D, Dhakal HP, Sahlberg KK, Schlichting E; Oslo Breast Cancer Research Consortium (OSBREAC), Børresen-Dale AL, Borgen E, Naume B, Eskeland R, Frigessi A, Tost J, Hurtado A, Kristensen VN.

Nat Commun. 2017 Nov 9;8(1):1379. doi: 10.1038/s41467-017-00510-x.

11.

Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency.

Davies H, Morganella S, Purdie CA, Jang SJ, Borgen E, Russnes H, Glodzik D, Zou X, Viari A, Richardson AL, Børresen-Dale AL, Thompson A, Eyfjord JE, Kong G, Stratton MR, Nik-Zainal S.

Cancer Res. 2017 Sep 15;77(18):4755-4762. doi: 10.1158/0008-5472.CAN-17-1083.

12.

The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer.

Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Møller EK, Fleischer T, Rødland E, Krohn M, Borgen E, Garred Ø, Olsen T, Vu P, Skjerven H, Fangberget A, Holmen MM, Schlitchting E, Wille E, Nordberg Stokke M, Moen Vollan HK, Kristensen V, Langerød A, Lundgren S, Wist E, Naume B, Lingjærde OC, Børresen-Dale AL, Engebraaten O.

Clin Cancer Res. 2017 Aug 15;23(16):4662-4670. doi: 10.1158/1078-0432.CCR-17-0160. Epub 2017 May 9.

13.

Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases.

Seeberg LT, Brunborg C, Waage A, Hugenschmidt H, Renolen A, Stav I, Bjørnbeth BA, Borgen E, Naume B, Brudvik KW, Wiedswang G.

Ann Surg Oncol. 2017 Aug;24(8):2113-2121. doi: 10.1245/s10434-017-5818-2. Epub 2017 Mar 3.

14.

Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer.

Egeland EV, Boye K, Park D, Synnestvedt M, Sauer T; Oslo Breast Cancer Consortium (OSBREAC), Naume B, Borgen E, Mælandsmo GM.

Breast Cancer Res Treat. 2017 Feb;162(1):127-137. doi: 10.1007/s10549-016-4096-1. Epub 2017 Jan 5.

PMID:
28058579
15.

Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing.

Demeulemeester J, Kumar P, Møller EK, Nord S, Wedge DC, Peterson A, Mathiesen RR, Fjelldal R, Zamani Esteki M, Theunis K, Fernandez Gallardo E, Grundstad AJ, Borgen E, Baumbusch LO, Børresen-Dale AL, White KP, Kristensen VN, Van Loo P, Voet T, Naume B.

Genome Biol. 2016 Dec 9;17(1):250.

16.

Comparison of Standard Catheters Versus Radial Artery-Specific Catheter in Patients Who Underwent Coronary Angiography Through Transradial Access.

Chen O, Goel S, Acholonu M, Kulbak G, Verma S, Travlos E, Casazza R, Borgen E, Malik B, Friedman M, Moskovits N, Frankel R, Shani J, Ayzenberg S.

Am J Cardiol. 2016 Aug 1;118(3):357-61. doi: 10.1016/j.amjcard.2016.05.010. Epub 2016 May 17.

PMID:
27269989
17.

Single cell analysis of cancer cells using an improved RT-MLPA method has potential for cancer diagnosis and monitoring.

Kvastad L, Werne Solnestam B, Johansson E, Nygren AO, Laddach N, Sahlén P, Vickovic S, Bendigtsen SC, Aaserud M, Floer L, Borgen E, Schwind C, Himmelreich R, Latta D, Lundeberg J.

Sci Rep. 2015 Nov 12;5:16519. doi: 10.1038/srep16519.

18.

The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer.

Silwal-Pandit L, Russnes H, Borgen E, Skarpeteig V, Moen Vollan HK, Schlichting E, Kåresen R, Naume B, Børresen-Dale AL, Farnebo M, Langerød A.

PLoS One. 2015 Oct 13;10(10):e0139965. doi: 10.1371/journal.pone.0139965. eCollection 2015.

19.

NUT expression in primary lung tumours.

Lund-Iversen M, Grøholt KK, Helland Å, Borgen E, Brustugun OT.

Diagn Pathol. 2015 Sep 5;10:156. doi: 10.1186/s13000-015-0395-9.

20.

Detection of Circulating Tumor Cells at Surgery and at Follow-Up Assessment to Predict Survival After Two-Stage Liver Resection of Colorectal Liver Metastases.

Brudvik KW, Seeberg LT, Hugenschmidt H, Renolen A, Schirmer CB, Brunborg C, Bjørnbeth BA, Borgen E, Naume B, Waage A, Wiedswang G.

Ann Surg Oncol. 2015 Nov;22(12):4029-37. doi: 10.1245/s10434-015-4482-7. Epub 2015 Mar 24.

PMID:
25801354
21.

Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.

Naume B, Synnestvedt M, Falk RS, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Sommer HH, Sætersdal AB, Rypdal MC, Bendigtsen Schirmer C, Wist EA, Borgen E.

J Clin Oncol. 2014 Dec 1;32(34):3848-57. doi: 10.1200/JCO.2014.56.9327. Epub 2014 Nov 3.

PMID:
25366688
22.

Circulating tumor cells in patients with metastatic castration resistant prostate cancer: exploratory findings at a tertiary referral hospital.

Fosså SD, Hess SL, Paus E, Borgen E.

Res Rep Urol. 2014 Sep 27;6:121-6. doi: 10.2147/RRU.S68477. eCollection 2014.

23.

Contralateral embolization of intima after transfemoral aortic valve replacement.

Chen O, Rao AS, Frankel R, Borgen E, Saunders PC, Rhee R, Crooke GA, Konstadt SN, Ribakove GH, Shani J.

JACC Cardiovasc Interv. 2014 Sep;7(9):e119-20. doi: 10.1016/j.jcin.2014.01.175. Epub 2014 Aug 13. No abstract available.

24.

Comparison of molecular and immunocytochemical methods for detection of disseminated tumor cells in bone marrow from early breast cancer patients.

Gilje B, Nordgård O, Tjensvoll K, Borgen E, Synnestvedt M, Smaaland R, Naume B.

BMC Cancer. 2014 Jul 15;14:514. doi: 10.1186/1471-2407-14-514.

25.

International study on inter-reader variability for circulating tumor cells in breast cancer.

Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothé F, Metallo J, Rouas G, Payne RE, Coombes R, Teufel I, Andergassen U, Apostolaki S, Politaki E, Mavroudis D, Bessi S, Pestrin M, Di Leo A, Campion M, Reinholz M, Perez E, Piccart M, Borgen E, Naume B, Jimenez J, Aura C, Zorzino L, Cassatella M, Sandri M, Mostert B, Sleijfer S, Kraan J, Janni W, Fehm T, Rack B, Terstappen L, Repollet M, Pierga JY, Miller C, Sotiriou C, Michiels S, Pantel K.

Breast Cancer Res. 2014 Apr 23;16(2):R43. doi: 10.1186/bcr3647.

26.

Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c.

Nygren MK, Tekle C, Ingebrigtsen VA, Mäkelä R, Krohn M, Aure MR, Nunes-Xavier CE, Perälä M, Tramm T, Alsner J, Overgaard J, Nesland JM, Borgen E, Børresen-Dale AL, Fodstad Ø, Sahlberg KK, Leivonen SK.

Br J Cancer. 2014 Apr 15;110(8):2072-80. doi: 10.1038/bjc.2014.113. Epub 2014 Feb 27.

27.

Circulating tumor cells in patients with colorectal liver metastasis predict impaired survival.

Seeberg LT, Waage A, Brunborg C, Hugenschmidt H, Renolen A, Stav I, Bjørnbeth BA, Brudvik KW, Borgen EF, Naume B, Wiedswang G.

Ann Surg. 2015 Jan;261(1):164-71. doi: 10.1097/SLA.0000000000000580.

PMID:
24509211
28.

Associations between tumor vascularization assessed by in vivo DCE-MRI and the presence of disseminated tumor cells in bone marrow in breast cancer patients at the time of diagnosis.

Nilsen LB, Fangberget A, Geier OM, Engebraaten O, Borgen E, Olsen DR, Seierstad T.

J Magn Reson Imaging. 2014 Dec;40(6):1382-91. doi: 10.1002/jmri.24502. Epub 2014 Jan 27.

PMID:
24470360
29.

Next-generation sequencing of disseminated tumor cells.

Møller EK, Kumar P, Voet T, Peterson A, Van Loo P, Mathiesen RR, Fjelldal R, Grundstad J, Borgen E, Baumbusch LO, Naume B, Børresen-Dale AL, White KP, Nord S, Kristensen VN.

Front Oncol. 2013 Dec 31;3:320. doi: 10.3389/fonc.2013.00320. eCollection 2013.

30.

The clinical impact of mean vessel size and solidity in breast carcinoma patients.

Mikalsen LT, Dhakal HP, Bruland ØS, Naume B, Borgen E, Nesland JM, Olsen DR.

PLoS One. 2013 Oct 11;8(10):e75954. doi: 10.1371/journal.pone.0075954. eCollection 2013.

31.

Clinical significance of disseminated tumour cells in non-small cell lung cancer.

Rud AK, Borgen E, Mælandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland Å, Jørgensen L, Brustugun OT, Fodstad Ø, Boye K.

Br J Cancer. 2013 Sep 3;109(5):1264-70. doi: 10.1038/bjc.2013.450. Epub 2013 Aug 13.

32.

Enhancing safety in behavioral emergency situations.

Pestka EL, Hatteberg DA, Larson LA, Zwygart AM, Cox DL, Borgen EE Jr.

Medsurg Nurs. 2012 Nov-Dec;21(6):335-41.

PMID:
23477025
33.

Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome.

Synnestvedt M, Borgen E, Schlichting E, Schirmer CB, Renolen A, Giercksky KE, Nesland JM, Naume B.

Breast Cancer Res Treat. 2013 Apr;138(2):485-97. doi: 10.1007/s10549-013-2439-8. Epub 2013 Mar 3.

PMID:
23456230
34.

Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study.

Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Schirmer C, Nesland JM, Naume B.

BMC Cancer. 2012 Dec 22;12:616. doi: 10.1186/1471-2407-12-616.

35.

Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact.

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM.

Histol Histopathol. 2012 Oct;27(10):1315-25. doi: 10.14670/HH-27.1315.

PMID:
22936450
36.

Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy.

Synnestvedt M, Borgen E, Russnes HG, Kumar NT, Schlichting E, Giercksky KE, Kåresen R, Nesland JM, Naume B.

Acta Oncol. 2013 Jan;52(1):91-101. doi: 10.3109/0284186X.2012.713508. Epub 2012 Aug 30.

PMID:
22934555
37.

Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.

Mathiesen RR, Borgen E, Renolen A, Løkkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lønning PE, Naume B.

Breast Cancer Res. 2012 Aug 14;14(4):R117. doi: 10.1186/bcr3242.

38.

Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness.

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM.

Histopathology. 2012 Sep;61(3):350-64. doi: 10.1111/j.1365-2559.2012.04223.x. Epub 2012 Jun 13.

PMID:
22690749
39.

High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer.

Mathiesen RR, Fjelldal R, Liestøl K, Due EU, Geigl JB, Riethdorf S, Borgen E, Rye IH, Schneider IJ, Obenauf AC, Mauermann O, Nilsen G, Christian Lingjaerde O, Børresen-Dale AL, Pantel K, Speicher MR, Naume B, Baumbusch LO.

Int J Cancer. 2012 Aug 15;131(4):E405-15. doi: 10.1002/ijc.26444. Epub 2011 Nov 9.

40.

The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients.

Molloy TJ, Bosma AJ, Baumbusch LO, Synnestvedt M, Borgen E, Russnes HG, Schlichting E, van't Veer LJ, Naume B.

Breast Cancer Res. 2011 Jun 14;13(3):R61. doi: 10.1186/bcr2898.

41.

Disseminated tumour cells as a prognostic biomarker in colorectal cancer.

Flatmark K, Borgen E, Nesland JM, Rasmussen H, Johannessen HO, Bukholm I, Rosales R, Hårklau L, Jacobsen HJ, Sandstad B, Boye K, Fodstad Ø.

Br J Cancer. 2011 Apr 26;104(9):1434-9. doi: 10.1038/bjc.2011.97. Epub 2011 Mar 29.

42.

Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis.

Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Jückstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, Naume B.

Clin Cancer Res. 2011 May 1;17(9):2967-76. doi: 10.1158/1078-0432.CCR-10-2515. Epub 2011 Mar 17.

43.

Lab-on-a-chip for the isolation and characterization of circulating tumor cells.

Stakenborg T, Liu C, Henry O, O'Sullivan CK, Fermer C, Roeser T, Ritzi-Lehnert M, Hauch S, Borgen E, Laddach N, Lagae L.

Conf Proc IEEE Eng Med Biol Soc. 2010;2010:292-4. doi: 10.1109/IEMBS.2010.5627655.

PMID:
21096963
44.

Hexaminolevulinate-mediated photodynamic purging of marrow grafts with murine breast carcinoma.

Čunderlíková B, Vasovič V, Sieber F, Furre T, Borgen E, Nesland JM, Peng Q.

Bone Marrow Transplant. 2011 Aug;46(8):1118-27. doi: 10.1038/bmt.2010.277. Epub 2010 Nov 8.

PMID:
21057550
45.

Automated genotyping of circulating tumor cells.

Stakenborg T, Liu C, Henry O, Borgen E, Laddach N, Roeser T, Ritzi-Lehnert M, Fermér C, Hauch S, O'Sullivan CK, Lagae L.

Expert Rev Mol Diagn. 2010 Sep;10(6):723-9. doi: 10.1586/erm.10.66.

PMID:
20843197
46.

Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.

Russnes HG, Vollan HKM, Lingjærde OC, Krasnitz A, Lundin P, Naume B, Sørlie T, Borgen E, Rye IH, Langerød A, Chin SF, Teschendorff AE, Stephens PJ, Månér S, Schlichting E, Baumbusch LO, Kåresen R, Stratton MP, Wigler M, Caldas C, Zetterberg A, Hicks J, Børresen-Dale AL.

Sci Transl Med. 2010 Jun 30;2(38):38ra47. doi: 10.1126/scitranslmed.3000611.

47.

Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern.

Effenberger KE, Borgen E, Eulenburg CZ, Bartkowiak K, Grosser A, Synnestvedt M, Kaaresen R, Brandt B, Nesland JM, Pantel K, Naume B.

Breast Cancer Res Treat. 2011 Feb;125(3):729-38. doi: 10.1007/s10549-010-0911-2. Epub 2010 May 7.

PMID:
20449649
48.

Breast carcinoma vascularity: a comparison of manual microvessel count and Chalkley count.

Dhakal HP, Bassarova A, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Giercksky KE, Nesland JM.

Histol Histopathol. 2009 Aug;24(8):1049-59. doi: 10.14670/HH-24.1049.

PMID:
19554512
49.

Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination.

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Giercksky KE, Nesland JM.

Clin Cancer Res. 2008 Apr 15;14(8):2341-50. doi: 10.1158/1078-0432.CCR-07-4214.

50.

Lab-on-chip for the isolation and characterization of circulating tumor cells.

Roeser T, Ritzi M, Drese KS, Laureyn W, Liu C, O'Sullivan CK, Ozalp VC, Fermer C, Nilsson O, Hauch S, Albert W, Borgen E, Nygre AO.

Conf Proc IEEE Eng Med Biol Soc. 2007;2007:6447-9. No abstract available.

PMID:
18003499

Supplemental Content

Loading ...
Support Center